Drug Profile
CJC 1004
Alternative Names: CCI 1004; DAC:T1; DAC:Thrombin inhibitorLatest Information Update: 16 Aug 2002
Price :
$50
*
At a glance
- Originator ConjuChem Biotechnologies
- Class Antithrombotics
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 16 Aug 2002 Discontinued - Phase-I for Thrombosis in USA (Intra-arterial)
- 27 May 2002 Phase-I clinical trials in Thrombosis in USA (Intra-arterial)
- 29 Jan 2002 ConjuChem has announced a sponsored research agreement with Almirall Prodesfarma in Spain